Cabergoline therapy of growth hormone &amp; growth hormone/prolactin secreting pituitary tumors (Q42644464)

4 November 2017

Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors (English)

1 reference

4 November 2017

Pamela U Freda

1

1 reference

4 November 2017

Carlos M Reyes

2

1 reference

4 November 2017

Abu T Nuruzzaman

3

1 reference

4 November 2017

Robert E Sundeen

4

1 reference

4 November 2017

Alexander G Khandji

5

1 reference

4 November 2017

Kalmon D Post

6

1 reference

4 November 2017

1 January 2004

1 reference

4 November 2017

1 reference

4 November 2017

7

1 reference

4 November 2017

1

1 reference

4 November 2017

21-30

1 reference

https://scigraph.springernature.com/pub.10.1023/b:pitu.0000044630.83354.f0

4 November 2017

0 references

1 reference

12 December 2020

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly

1 reference

12 December 2020

Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity

1 reference

12 December 2020

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

12 December 2020

The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly

1 reference

12 December 2020

Effect of different dopaminergic agents in the treatment of acromegaly

1 reference

12 December 2020

Somatostatin analogs in acromegaly

1 reference

12 December 2020

Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly

1 reference

12 December 2020

Cabergoline treatment of acromegaly: a preliminary dose finding study

1 reference

12 December 2020

Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm

1 reference

12 December 2020

Growth hormone and prolactin secretion in acromegaly: correlations between hormonal dynamics and immunocytochemical findings

1 reference

12 December 2020

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

12 December 2020

Clinical-pathological correlations of pituitary tumours.

1 reference

12 December 2020

Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients

1 reference

12 December 2020

Treatment of acromegaly with dopamine agonists

1 reference

12 December 2020

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation

1 reference

12 December 2020

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

12 December 2020

Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline

1 reference

12 December 2020

1 reference

12 December 2020

In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.

1 reference

12 December 2020

Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients

1 reference

12 December 2020

10.1023/B:PITU.0000044630.83354.F0

Identifiers

DOI

1 reference

Dimensions Publication ID

4 November 2017

0 references

1 reference